aTyr Pharma (LIFE) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to aTyr Pharma (LIFE) Misses Q2 EPS by 2c

aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update

August 14, 2018 4:05 PM EDT

SAN DIEGO , Aug. 14, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the second quarter ended June 30, 2018.

We have made important advancements in the development of our lead product candidate, ATYR1923, during the recent months, said Sanjay Shukla, M.D., M.S., President and CEO of aTyr. We have completed our Phase 1 clinical trial for ATYR1923 and are poised to initiate a clinical trial by the end of this year in patients with... More